MedTrace Logo

Pharmacological Effects of Neurapas® Balance and Pascoflair® 425 mg on Brain Activity in Healthy Volunteers

NCT01047605 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2010-05-17

No results posted yet for this study

Summary

To evaluate the pharmacological effects of two herbal medicinal products (Neurapas balance and Pascoflair 425 mg) in comparison to placebo on brain activity.

Conditions

  • Healthy

Interventions

DRUG

Neurapas balance

6 tablets single dose

DRUG

Pascoflair 425 mg

3 tablets , single dose

DRUG

P-Tabletten weiß

3 tablets, single dose

Sponsors & Collaborators

  • Pascoe Pharmazeutische Praeparate GmbH

    lead INDUSTRY

Principal Investigators

  • Winfried Wedekind, MD, PhD · Neurocoed AG, Sportparkstr. 9, D-35578 Wetzlar, Germany

  • Wilfried Dimpfel, Prof · Neurocode AG, Sportparkstr. 9, D-35578 Wetzlar, Germany

  • Anja Braschoss, MD · Pascoe Pharmazeutische Praeparate GmbH

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01047605 on ClinicalTrials.gov